Skywork Super Agents is not just an "AI-powered Office," but also a versatile expert in multimodal content creation. It ...

Q1 2026 Earnings Call Transcript May 22, 2025 Autodesk, Inc. beats earnings expectations. Reported EPS is $2.29, expectations ...

Q4 2025 Earnings Call Transcript May 20, 2025 Operator: Welcome to the James Hardie Fiscal Fourth Quarter 2025 Earnings ...

NEW YORK--(BUSINESS WIRE)--HG Vora Capital Management, LLC (together with its affiliates, “HG Vora”) today released a comprehensive presentation highlighting the urgent need for change on the ...

"We are honored that our Trial in Progress poster has been accepted for presentation at ASCO 2025 ... Gear advertisements and other marketing efforts towards your interests.

Your go-to for B2B Marketing Training and Consulting backed by data science, psychology, and—our secret weapon—real-world experience. Join 350,000+ marketers who rely on MarketingProfs for B2B ...

Highlights How the Three Independent Director Candidates Nominated by HG Vora – William Clifford, Johnny Hartnett and Carlos Ruisanchez – Can Help Restore Value at PENN Urges Shareholders to Vote for ...

An oral presentation will feature ALLO-316, an investigational AlloCAR T product targeting CD70. ALLO-316 is currently being studied in patients with advanced or metastatic renal cell carcinoma (RCC).

Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd – – Encore presentation planned at EHA 2025 ...

An oral presentation will feature ALLO-316, an investigational AlloCAR T product targeting CD70. ALLO-316 is currently being studied in patients with advanced or metastatic renal cell carcinoma (RCC).

WILMINGTON, N.C. (WECT) - After a controversial election cycle that included a delay in counting nearly 2,000 ballots, subsequent rebuke from the state elections board and county leadership, and a ...

Immix Biopharma (IMMX) today reported ASCO abstract results from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201 demonstrating strong efficacy and favorable safety. “We are ...